dementia

Translating Genetic Findings Into Dementia Treatments

Tracing the Path From Bench to Bedside

brain behind DNA molecule

When IRP graduate student Pilar Alvarez Jerez looked at the results of a recent experiment, she noticed that when a particular genetic variant is present in a gene called GBA1, it causes a change in the gene's activity. The GBA1 variant, which is associated with Parkinson’s disease and Lewy body dementia, was discovered last year in people of African ancestry by researchers at NIH’s Center for Alzheimer's and Related Dementias (CARD). It appears to suppress the gene’s ability to make a functional version of an enzyme that helps brain cells recycle their proteins.

“This was an interesting finding, but it still didn’t answer how the variant was functioning to lower enzyme activity,” Pilar says.

From Friend to Foe: When the Immune System Turns on the Brain

IRP Research is Exploring the Role of Immune Cells in Dementia

illustration of fire trucks rushing to put out a fire in the brain

If you visit a lab at NIH’s Center for Alzheimer’s and Related Dementias (CARD), you may find yourself surrounded by several robots hard at work nurturing the hundreds of sets of genetically modified stem cells that CARD scientists use to study the illnesses that give CARD its name. Many of these cells will be coaxed to mature into the neurons that power our movements, thoughts, and memories — but not all of them. Neurons have long received the lion share of dementia researchers’ attention, understandable seeing as the visible symptoms of Alzheimer’s disease are closely linked to a build-up of proteins — amyloid-beta and misfolded tau — that damage neurons. However, neurons aren’t the only brain cells involved in dementia.

Jekyll-and-Hyde Gene Has Dual Influences on Dementia Risk

IRP’s Priyanka Narayan Explores How the ApoE Gene Affects Fat Management in the Brain

two DNA molecules overlaid on top of a brain

Just as Dr. Jekyll and Mr. Hyde exhibited the extremes of good and bad qualities in a single man, IRP Stadtman Investigator Priyanka Narayan, Ph.D., is showing how a single gene can both protect against and raise the risk for Alzheimer’s disease and other dementias. As we observe Alzheimer’s and Brain Awareness month this June, we talked with Dr. Narayan about her work.

“Our research focuses on understanding fundamental cell biology in brain cells and how genetic factors affecting that biology can predispose individuals to Alzheimer's disease,” Dr. Narayan says. “More recently, we’ve become interested in protective factors that make people more resistant to getting Alzheimer’s disease and other forms of neurodegenerative diseases as well.”

Out of the Clinic and Into the Lab

Visiting Medical Students Look Back on IRP Research Experience

Alex Valenzuela

When patients are affected by complex and poorly understood medical problems, it can only be an advantage when their doctors have one foot in the exam room and another in a laboratory studying the disease. However, physicians don’t accrue scientific skills on their own. Rather, they often must venture outside of their medical education to gain experience in research via programs like NIH’s Medical Research Scholars Program (MRSP).

The MRSP allows medical students from across the United States to spend a year working in IRP labs alongside seasoned scientists. The 50 medical students and one dental student selected as 2022 Medical Research Scholars recently finished their time at NIH after arriving on campus last July. Between classes, clinical rounds, study sessions, and exams, five of those young men and women found the time to describe their experience at NIH to the “I Am Intramural” blog, so read on to get a taste of what the MRSP has to offer our nation’s aspiring physicians.

Data Mining for Dementia Clues

IRP Research Examines Under-Appreciated Factors in Alzheimer’s Disease

brain with red area in the middle representing inflammation

This June, the observance of Alzheimer’s and Brain Awareness month reminds us just how devastating the impact of Alzheimer’s and other dementias is across the world. About 55 million people are currently living with Alzheimer’s disease or related dementias such as frontotemporal dementia and Lewy body dementia. This includes the estimated 6.7 million people in the U.S. over age 65 with Alzheimer’s disease, a population whose cognitive decline imposes huge financial costs on the American economy and often unrecognized burdens on the unpaid family members who provide care for those patients.

While the disease has been a target of intensive investigation ever since Alois Alzheimer first discovered clumps of amyloid beta protein and tangles of tau in the brain of a deceased patient in 1906, scientists have made only modest progress in treating it. Efforts to design drugs targeting the abnormal globs of amyloid and tau thought to cause Alzheimer’s have met with only limited success. That’s why IRP investigator Keenan Walker, Ph.D., is taking a different approach: exploring the link between dementia risk and the immune system.

Toxic Protein and Aging Combine Forces to Drive Brain Disease

IRP Study Suggests New Therapeutic Targets for Pair of Age-Related Illnesses

older man

Aging wears down all parts of our bodies, from our bones to our brains. It’s no surprise, then, that it’s the main risk factor for neurological illnesses like Parkinson’s disease and dementia. However, the precise reason why has long remained a mystery. New IRP research suggests that the aged brain is a fertile ground for the spread of a harmful protein associated with several neurological diseases, and that the toxic protein itself ages immune cells in the brain.

An Unlikely Target in the Fight Against Alzheimer’s

IRP Researchers Find Link Between Dementia and Byproducts of Cholesterol Breakdown

old man in nursing home

When most people think about Alzheimer’s disease, the liver is probably the organ least likely to come to mind. Yet recent IRP research suggests that molecules called bile acids, which are synthesized in the liver, may influence the development of Alzheimer’s disease. In honor of Brain Awareness Week this week, we’re diving into that work to learn how such an unlikely target could help lead to new treatments for Alzheimer’s and other forms of dementia.

To date, efforts to develop therapies for Alzheimer’s disease, which affects more than 6 million Americans over the age of 65, have achieved little success. Many scientists are focused on proteins in the brain as potential treatment targets, including the ‘amyloid-beta’ protein now infamous amongst Alzheimer’s researchers. In contrast, IRP senior investigator Madhav Thambisetty, M.D., Ph.D., has been exploring the role that cholesterol might play in the development of Alzheimer’s and vascular dementia, which is marked by microscopic bleeding and blood vessel blockage and is the second most common form of dementia.

To Boost Learning, Timing May Be Everything

New Strategy Could Enhance Benefits of Therapeutic Brain Stimulation

person holding a stopwatch

Electricity can do crazy things to the brain. While it can’t bring back the dead à la Frankenstein or give you new memories like in Total Recall, many scientists believe electrical stimulation could one day help patients with movement or memory problems regain those capabilities. New IRP research bolsters this idea by showing that a brain stimulation technology called transcranial magnetic stimulation (TMS) significantly boosts motor skill learning when precisely administered during specific periods of brain activity.

NIH Summer Interns Show Off in Poster Exhibitions

Budding Scientists Present Their Research During Three-Day Virtual Event

Deeya Garg

Although NIH’s 2021 Summer Internship Program (SIP) was fully virtual this year, that didn’t stop the hundreds of participating high school, college, and graduate students from contributing to a variety of important IRP research projects. More than 500 students who worked in NIH labs this summer presented their work during this year’s Summer Presentation Week, which took place August 3-5.

I sifted through the lengthy list of presenters at the event and spoke with a diverse group of young men and women who spent their summers expanding our knowledge of human health and biology. Read on to learn about these promising future scientists and doctors and the research they completed this summer.

Rare Genetic Mutation Links Two Neurological Diseases

Globe-Spanning Collaboration Connected ‘Viking Gene’ to Dementia and ALS

A man with ALS uses a head-mounted laser pointer to communicate with his wife by pointing to letters and words on a communication board

June was an important month in the life of baseball great Lou Gehrig. It was the month he was born and the month he was first picked for the Yankees’ starting lineup. Sadly, it was also the month in 1939 when he was diagnosed with the neurological disease that bears his name — Lou Gehrig’s disease, also known as amyotrophic lateral sclerosis (ALS) — and the month he died of that disease two years later. It is appropriate then that ALS Awareness Day is observed on June 21 as a day of hope for those searching for effective treatments and, ultimately, a cure.

IRP senior investigator Bryan J. Traynor, M.D., Ph.D., a neurologist at the National Institute on Aging (NIA), is one of the people leading that search. Best known for his work unraveling the genetic causes of ALS and frontotemporal dementia (FTD), he led an international consortium of researchers that uncovered a mutation on chromosome 9 that is the most common ‘familial’ cause of both ALS and FTD. In fact, this mutation, which disrupts the function of the C90RF72 gene, is responsible for 40 percent of all familial cases of ALS and FTD in European and North American populations, meaning cases in which a family member also has the disease. The discovery, published in 2011, revolutionized the scientific understanding of neurodegenerative diseases and the relationships between them. It also suggested a potential target for future gene therapies.